Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous IKDC-like cells in metastatic cancer
NCT02661685Phase 1Completed
- Sponsor
- National Defense Medical Center
- Start
- May 2016
- Primary completion
- Oct 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous IKDC-like cells in solid tumor, sponsored by National Defense Medical Center. Primary endpoint: Evaluation of subject with Grade 3 or above adverse events. Started May 2016; status: completed.
02
Drugs
autologous IKDC-like cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02661685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661685.